Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
Merrimack is conducting a research study to see if an experimental drug, called MM-093, is
safe and effective in the treatment of psoriasis. MM-093 is a genetically engineered version
of a naturally occurring protein called alpha fetoprotein (AFP). Adults normally have very
small amounts of AFP in their bloodstream. However, during pregnancy, AFP levels in both the
mother and the fetus are much higher than normal. It has been observed that some women with
psoriasis and other autoimmune diseases such as rheumatoid arthritis have fewer symptoms
during pregnancy, particularly during the third trimester. At this time, the levels of AFP in
the blood of the mother and fetus are the highest. This observation led Merrimack to begin
examining MM-093 as a potential treatment for psoriasis. This study is designed to further
test the safety and effectiveness of MM-093 in patients with psoriasis.